Maravai Lifesciences reports Q4 adjusted EPS 1c, consensus (1c)

Reports Q4 revenue $74.141M, consensus $64.38M. “We closed out a challenging 2023 with better than forecasted demand for our Nucleic Acid Production products, including for CleanCap and custom chemistry,” said Trey Martin, Chief Executive Officer of Maravai. “Thanks to our team’s strong execution, the cost reductions we implemented in the fourth quarter and our revenue outperformance, we delivered a 28% adjusted EBITDA margin in the fourth quarter.”